NANOSONICS LIMITED (NAN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NAN - NANOSONICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.58
Index: ASX200 | ASX300 | ALL-ORDS

Nanosonics is an Australian medical device company manufacturing high level disinfection systems to reduce the spread of infection. Founded in 2001, the company listed on the ASX in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.45

20 Nov
2024

0.050

OPEN

$3.43

1.47%

HIGH

$3.50

400,559

LOW

$3.42

TARGET
$3.513 1.8% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
NAN: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 4.3 5.3 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx - 35.2% 23.8% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 66.8 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx4.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx171.6 M
Book Value Per Share xxxxxxxxxxxxxxx60.1
Net Operating Cash Flow xxxxxxxxxxxxxxx22.8 M
Net Profit Margin xxxxxxxxxxxxxxx7.56 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx7.50 %
Return on Invested Capital xxxxxxxxxxxxxxx7.21 %
Return on Assets xxxxxxxxxxxxxxx5.54 %
Return on Equity xxxxxxxxxxxxxxx7.50 %
Return on Total Capital xxxxxxxxxxxxxxx4.58 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx20.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx6 M
Total Debt xxxxxxxxxxxxxxx9 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx130 M
Price To Book Value xxxxxxxxxxxxxxx4.97

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx2.5 M
Capex % of Sales xxxxxxxxxxxxxxx1.47 %
Cost of Goods Sold xxxxxxxxxxxxxxx44 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx119 M
Research & Development xxxxxxxxxxxxxxx30 M
Investments - Total xxxxxxxxxxxxxxx1 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.1

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

28/08/2024

5

Sell

$3.15

-8.70%

Sell rating maintained while Citi has bumped up its price target for Nanosonics to $3.15 from $2.70. The mid-point of management's guidance falls in line with market consensus forecasts for FY25, the broker highlights.

Earnings estimates have received quite the noticeable bump higher, even as Coris-related costs continue to drag on margins, as the broker points out.

The company had pre-reported its sales numbers but upon release of FY24 financials net profit was higher than forecasts and operating profit proved in line.

Citi believes implied EBIT guidance of $10.3m for FY25 (at mid-point) is in line with market consensus at $10.5m.

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

02/09/2024

3

Hold

$3.12

-9.57%

Nanosonics released FY24 results in line with the July trading update. Canaccord Genuity notes North American volumes improved in the 2H. It's thought Hospital capex budgets have recovered.

Management reiterated Coris timelines and was optimistic on the International new installed base growth in the longer-term to 1,000 new units per year on improving fundamentals for automated disinfection.

FY25 guidance was in line with expectations, with management anticipating the gross margin will return to the historic 77-79% range.

The target rises to $3.12 from $2.83. The Hold rating is unchanged.

FORECAST
Canaccord Genuity forecasts a full year FY25 EPS of 3.00 cents.
Canaccord Genuity forecasts a full year FY26 EPS of 4.90 cents.
Access Extra Coverage Research History >

NAN STOCK CHART

FNArena News on NAN

1
Rudi’s View: Banks, Miners & Quality Small Caps

Sep 26 2024 - Rudi's View
2
August Result Season 2024: The Wrap

Sep 24 2024 - Feature Stories
3
Rudi’s View: Key Picks, Best Buys & Conviction Calls

Sep 12 2024 - Rudi's View
4
FNArena Corporate Results Monitor – 06-09-2024

Sep 06 2024 - Australia
5
Australian Broker Call *Extra* Edition – Sep 02, 2024

Sep 02 2024 - Daily Market Reports

Latest Medical Equipment & Devices News

1
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
2
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
3
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
4
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
5
ResMed Silences The Doubters

Apr 29 2024 - Australia
6
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
7
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
8
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
9
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
10
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps